Phase II open-label study of single-agent hydroxyurea for treatment of mast cell tumours in dogs

Veterinary and Comparative Oncology

Volumn 8, Issue 2, 2010, Pages 103-111

  Rassnick, K M ^a   Al Sarraf, R ^b   Bailey, D B ^b   Chretin, J D ^c   Phillips, B ^d   Zwhalen, C H ^e  

^a Department of Obstetrics Gynecology   (United States)

^b Animal Emergency and Referral Associates   (United States)

^c Veterinary Centers of America   (United States)

^d Veterinary Specialty Hospital   (United States)

^e Southern California Veterinary Specialty Hospital   (United States)

Author keywords

Chemotherapy; Oncology; Small animal

Indexed keywords

ANTINEOPLASTIC AGENT; HYDROXYUREA;

ANIMAL; ANIMAL DISEASE; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DOG; DOG DISEASE; DRUG ADMINISTRATION; FEMALE; LEUKOCYTE COUNT; MALE; MASTOCYTOMA; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME; CHEMICALLY INDUCED; DOG DISEASES; MASTOCYTOMA, SKIN; VETERINARY;

ANIMALS; ANTINEOPLASTIC AGENTS; DOG DISEASES; DOGS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HYDROXYUREA; LEUKOCYTE COUNT; MALE; MASTOCYTOMA, SKIN; PROSPECTIVE STUDIES; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANIMALIA; CANIS FAMILIARIS;

EID: 77953948181     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2010.00211.x     Document Type: Article

References (33)

1. McCaw DL, Miller MA, Ogilvie GK, Withrow SJ, Brewer WG, Klein MK, Bell FW, Anderson SK. Response of canine mast cell tumors to treatment with oral prednisone. Journal of Veterinary Internal Medicine 1994, 8:406-408.
2. Stanclift RM, Gilson SD. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs. Journal of the American Veterinary Medical Association 2008, 232:53-62.
3. Rassnick KM, Moore AS, Williams LE, London CA, Kintzer Engler SJ, Cotter SM. Treatment of canine mast cell tumors with CCNU (lomustine). Journal of Veterinary Internal Medicine 1999, 13:601-605.
4. Rassnick KM, Bailey DB, Flory AB, Balkman CE, Kiselow MA, Intile JL, Autio K. Efficacy of vinblastine for treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine 2008, 22:1390-1396.
5. Henry CJ, Downing S, Rosenthal RC, Klein MK, Meleo K, Villamil JA, Fineman LS, McCaw DL, Higginbotham ML, McMichael J. Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs. American Journal of Veterinary Research 2007, 68:1246-1251.
6. Thamm DH, Mauldin EA, Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor-41 cases (1992-1997). Journal of Veterinary Internal Medicine 1999, 13:491-497.
7. Vickery KR, Wilson H, Vail DM, Thamm DH. Dose-escalating vinblastine for the treatment of canine mast cell tumour. Veterinary and Comparative Oncology 2008, 6:111-119.
8. Camps-Palau MA, Leibman NF, Elmslie R, Lana SE, Plaza S, McKnight JA, Risbon R, Bergman PJ. Treatment of canine mast cell tumours with vinblastine, cyclophosphamide and prednisone: 35 cases (1997-2004). Veterinary and Comparative Oncology 2007, 5:156-167.
9. Cooper M, Tsai X, Bennet P. Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases. Veterinary and Comparative Oncology 2009, 7:196-206.
10. Peterson ME, Randolph JF. Diagnosis of canine primary polycythemia and management with hydroxyurea. Journal of the American Veterinary Medical Association 1982, 180:415-418.
11. Bass MC, Schultze AE. Essential thrombocythemia in a dog: case report and literature review. Journal of the American Animal Hospital Association 1998, 34:197-203.
12. MacEwen EG, Drazner FH, McClelland AJ, Wilkins RJ. Treatment of basophilic leukemia in a dog. Journal of the American Veterinary Medical Association 1975, 166:376-380.
13. Mears EA, Raskin RE, Legendre AM. Basophilic leukemia in a dog. Journal of Veterinary Internal Medicine 1997, 11:92-94.
14. Fine DM, Tvedten HW. Chronic granulocytic leukemia in a dog. Journal of the American Veterinary Medical Association 1999, 214:1791-1812.
15. Perkins M, Watson A. Successful treatment of hypereosinophilic syndrome in a dog. Australian Veterinary Journal 2001, 79:686-689.
16. Marconato L, Bonfanti U, Fileccia I. Unusual dermatological toxicity of hydroxyurea in two dogs with spontaneously occurring tumours. Journal of Small Animal Practice 2007, 48:514-517.
17. Moore KW, Stepien RL. Hydroxyurea for treatment of polycythemia secondary to right-to-left shunting patent ductus arteriosus in 4 dogs. Journal of Veterinary Internal Medicine 2001, 15:418-421.
18. Wray JD. Methaemoglobinaemia caused by hydroxycarbamide (hydroxyurea) ingestion in a dog. Journal of Small Animal Practice 2008, 49:211-215.
19. Hess PW, MacEwen EG, McClelland AJ. Chemotherapy for canine and feline tumors. Journal of the American Animal Hospital Association 1976, 12:350-358.
20. Gerritsen RJ, Teske E, Kraus JS, Rutteman GR. Multi-agent chemotherapy for mast cell tumours in the dog. Veterinary Quarterly 1998, 20:28-31.
21. Chu E, DeVita VT. Principles of cancer management: chemotherapy. Cancer: Principles and Practice of Oncology 2001, 289-306. DeVita VT, Hellman SRosenberg SA. In:, 6th edn., eds.,, Philadelphia, Lippincott Williams & Wilkins
22. McCaw DL, Miller MA, Bergman PJ, Withrow SJ, Moore AS, Knapp DW, Fowler D, Johnson JC. Vincristine therapy for mast cell tumors in dogs. Journal of Veterinary Internal Medicine 1997, 11:375-378.
23. Veterinary and Comparative Oncology 2004, 2:195-213. Veterinary co-operative oncology group common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0.
24. Frei E, Elias A, Wheeler C, Richardson P, Hryniuk W. The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Clinical Cancer Research 1998, 4:2027-2037.
25. Paz-Ares L, Donehower R. Hydroxyurea. Cancer Chemotherapy and Biotherapy: Principles and Practice 2001, 315-328. Chabner BA, Longo DL. In:, 3rd edn., eds.,, Philadelphia, Lippincott Williams & Wilkins
26. Simon R. Clinical trials in cancer. Cancer Principles & Practice of Oncology 2001, 521-538. Devita VTHellman SRosenberger SA. In:, 6th edn., eds.,, Philadelphia, Lippincott Williams & Wilkins
27. Bergsagel DE, Frenkel EP, Alfrey CP, Thurman WG. Megaloblastic erythropoiesis induced by hydroxyurea (NSC-32065). Cancer Chemotherapy Reports 1964, 40:15-17.
28. Endicott MM, Charney SC, McKnight JA, Loar AS, Barger AM, Bergman PJ. Clinicopathological findings and results of bone marrow aspiration in dogs with cutaneous mast cell tumours: 157 cases (1999-2002). Veterinary and Comparative Oncology 2007, 5:31-37.
29. Frenkel EP, Skinner WN, Smiley JD. Studies on a metabolic defect induced by hydroxyurea (NSC-32065). Cancer Chemotherapy Reports 1964, 40:19-22.
30. Ruzzon E, Randi ML, Tezza F, Luzzatto G, Scandellari R, Fabris F. Leg ulcers in elderly on hydroxyurea: a single center experience in Ph- myeloproliferative disorders and review of literature. Aging Clinical and Experimental Research 2006, 18:187-190.
31. Engstrom KG, Lofvenberg E. Treatment of myeloproliferative disorders with hydroxyurea: effects on red blood cell geometry and deformability. Blood 1998, 91:3986-3991.
32. London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, Hintermeister JG, Bergman PJ, Couto GC, Mauldin GN, Michels GM. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clinical Cancer Research 2009, 15:3856-3865.
33. Hahn KA, Ogilvie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, Powers B, Leventhal PS, Kinet JP, Palmerini F, Dubreuil P, Moussy A, Hermine O. Masitinib is safe and effective for the treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine 2008, 22:1301-1309.